Vessel-associated microglia are differentially activated and distributed in relation to systemic infection and

Oliver Milner1, Robert A Fisher1, Daniel J Asby1

  • 1Cerebrovascular and Dementia Research Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

PubMed

Insights

Vessel-associated microglia (VAM) are elevated in Alzheimer's disease (AD) and altered by systemic infection (SI), contributing to cerebrovascular dysfunction. This study reveals VAM

Area of Science:

  • Neuroscience
  • Neuropathology
  • Immunology

Background:

  • Vessel-associated microglia (VAM) are key components of the neurovascular unit.
  • VAM are implicated in cerebrovascular injury and blood-brain barrier (BBB) dysfunction in Alzheimer's disease (AD).
  • The role of VAM in AD, particularly with co-occurring systemic infection (SI), requires further investigation.

Purpose of the Study:

  • To investigate alterations in VAM distribution and activation in AD.
  • To examine the impact of systemic infection (SI) on VAM in AD.
  • To explore the relationship between VAM and cerebrovascular dysfunction markers.

Main Methods:

  • Neuropathological analysis of temporal cortex and white matter from AD and control groups (with/without SI).
  • Quantification of VAM density using microglial markers (Iba1, HLA-DR, CD68) near CD31-labelled microvessels.
  • Correlation analysis with brain cytokine levels and markers of cerebral perfusion and BBB leakiness.

Main Results:

  • Elevated Iba1+ VAM density observed in both SI and AD groups compared to controls.
  • Increased CD68+ VAM (phagocytosis marker) in both AD and AD + SI groups.
  • VAM markers correlated with pro-inflammatory cytokines in AD + SI, and cerebrovascular dysfunction markers in controls and AD.

Conclusions:

  • VAM distribution is elevated in AD and significantly altered by systemic infection.
  • These VAM alterations represent independent and synergistic contributors to cerebrovascular dysfunction in AD.
  • Findings highlight VAM as a critical factor in AD neuropathology and its interaction with systemic factors.